



# Platelet-Rich Plasma (PRP) in Cardiothoracic Surgery

Application of PRP in sternal closure has been shown to **promote earlier wound healing and improved postoperative outcomes.**<sup>1-4</sup>

## 0.2%-8%

of patients undergoing cardiac surgery experience complications (dehiscence and infection) following sternotomy.<sup>5</sup>


PRP-augmented sternal closure **reduced hospital readmission rate** within 30 days of operation.<sup>6</sup>

Hospital Readmission Rate (per 1000 patients)



PRP significantly **reduces the incidence of surgical site infections and deep sternal wound infections.**<sup>6</sup>

Sternal wound infection rate (n=2000)<sup>6</sup>




The mean cost of deep and superficial sternal wounds for a single patient is

## \$1,256,960.

This cost is **reduced by >50%** when augmented with PRP to an average of

## \$593,791

for a single patient.<sup>6</sup>



The Angel® system is the only fully-automated system with one-button automation to prepare customized PRP formulations.



**Adjustable Cellular Concentrations**  
Adjustable platelet and leukocyte concentrations in flexible processing volumes from 40 mL-180 mL.



**Proprietary 3-Sensor Technology**  
Platelet sensor system uses the principles of light absorption by cells to achieve precise separation.

The information contained in this brochure is not medical advice and is not meant to be a substitute for the advice provided by a surgeon or other qualified medical professional on the use of these products. You should talk with your physician or health care provider for more information about your health condition and whether Arthrex products might be appropriate for you. The surgeon who performs any surgical procedure is responsible for determining and using the appropriate techniques for surgical procedures on each individual patient. Arthrex recommends that surgeons be trained on the use of any particular product before using it in surgery. A surgeon must always rely on their own professional medical judgment when deciding whether to use a particular product when treating a particular patient. A surgeon must always refer to the package insert, product label, and/or directions for use before using any Arthrex product. Postoperative management is patient-specific and dependent on the treating professional's assessment. Individual results will vary and not all patients will experience the same postoperative activity level or outcomes. Products may not be available in all markets because product availability is subject to the regulatory approvals and medical practices in individual markets. Please contact Arthrex if you have questions about the availability of products in your area.

**References**

1. Trowbridge CC, Stammers AH, Woods E, Yen BR, Klayman M, Gilbert C. Use of platelet gel and its effects on infection in cardiac surgery. *J Extra Corpor Technol.* 2005;37(4):381-386.
2. Englert SJ, Estep TH, Ellis-Stoll CC. Autologous platelet gel applications during cardiovascular surgery: effect on wound healing. *J Extra Corpor Technol.* 2005;37(2):148-152.
3. Vang SN, Brady CP, Christensen KA, et al. Autologous platelet gel in coronary artery bypass grafting: effects on surgical wound healing. *J Extra Corpor Technol.* 2007;39(1):31-38.
4. Jameson CA. Autologous platelet concentrate for the production of platelet gel. *LabMed.* 2007;38:39-42.
5. Schimmer C, Sommer SP, Bensch M, Leyh R. Primary treatment of deep sternal wound infection after cardiac surgery: a survey of German heart surgery centers. *Interact Cardiovasc Thorac Surg.* 2007;6(6):708-711. doi:10.1510/icvts.2007.164004
6. Patel AN, Seizman CH, Kumptani GS, McKellar SH, Bull DA. Evaluation of autologous platelet rich plasma for cardiac surgery: outcome analysis of 2000 patients. *J Cardiothorac Surg.* 2016;11(1):62. doi:10.1186/s13019-016-0452-9

